Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin in acute heart failure
NL-OMON45125Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Serelaxin + standard therapy with Placebo + standard therapy (2 arms). Primary endpoints: Time to confirmed cardiovascular death and Time to first worsening heart failure event. Started Dec 2013; status: active, not recruiting.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NL-OMON45125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45125.